We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

STANDARD DIAGNOSTICS INC.

Standard Diagnostics develops rapid diagnostic tests that make it possible to diagnose various diseases at an earlier... read more Featured Products: More products

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Prototype Rapid Tests Evaluated for Human African Trypanosomiasis

By LabMedica International staff writers
Posted on 07 Jan 2015
Print article
Standard Diagnostics\' lateral flow rapid diagnostic test (RDT) for Trypanosoma brucei gambiense, human African trypanosomiasis (HAT)
The lateral flow rapid diagnostic test (RDT) for Trypanosoma brucei gambiense, human African trypanosomiasis (HAT) (Photo courtesy of STANDARD DIAGNOSTICS INC.)
The diagnosis of human African trypanosomiasis (HAT) remains a challenge both for active screening, which is critical in control of the disease and in the point-of-care scenario where early and accurate diagnosis is essential.

The most prevalent species of trypanosome causing HAT, Trypanosoma brucei gambiense, presents a diagnostic challenge and while early diagnosis is essential for effective treatment and also to control transmission, symptoms are nonspecific and parasitological diagnosis is laborious and technically difficult.

Scientists at the University of Aberdeen (UK) and their Swiss colleagues carried out a retrospective study using clinical samples of heparinized plasma that were obtained from 250 T. b. gambiense patients and 250 endemic controls. The infection status of patients was confirmed by observation of parasites in the blood, lymphatic system or cerebrospinal fluid, and this provided the reference standard.

Three rapid diagnostic tests (RDT) were evaluated in the study. A registered and commercialized RDT called SD BIOLINE HAT (Standard Diagnostics, Inc., (SD); Yongin, Republic of Korea), that is based on two native variable surface glycoproteins (VSGs). A prototype RDT developed by SD that is based on Baculovirus-expressed recombinant VSG antigens. The third RDT was a prototype RDT that is based on recombinant invariant type-1 trans-membrane domain surface glycoproteins (ISG65) and native VSG (MITat 1.4) antigens developed by BBI Solutions (Cardiff, UK), and called BBI.

The sensitivity and specificity of each RDT was calculated for each reader and each duplicate test. The prototype devices were not inferior in sensitivity or specificity to the SD BIOLINE HAT at the 5% margins, while one of the devices (BBI) had significantly superior sensitivity. Analysis of the performance of individual antigens was used to model new antigen combinations to be explored in development of the next generation of HAT RDTs. The modelling showed that an RDT using two recombinant antigens (rLiTat1.5 and rISG65) would give a performance similar to the best devices in the study, and would also offer the most robust performance under deteriorating field conditions.

The authors concluded that both SD BIOLINE HAT and the prototype devices performed comparably well to one another and also to the published performance range of the card agglutination test for trypanosomiasis in sensitivity and specificity. The performance of individual antigens enabled the team to predict that an all-recombinant antigen RDT can be developed with an accuracy equivalent to SD BIOLINE HAT. Such an RDT would have advantages in simplified manufacture, lower unit cost and assured reproducibility. The study was published on December 18, 2014, in the journal Public Library of Science Neglected Tropical Diseases.

Related Links:

University of Aberdeen
Standard Diagnostics, Inc. 
BBI Solutions 


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.